Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico

被引：0

作者：

Salinas-Escudero, Guillermo ^{[1
]}

Martinez-Valverde, Silvia ^{[1
]}

Reyes-Lopez, Alfonso ^{[1
]}

Garduno-Espinosa, Juan

Munoz-Hernandez, Onofre

Granados-Garcia, Victor ^{[2
]}

Rely, Kely ^{[3
]}

机构：

[1] Hosp Infantil Mexico Dr Federico Gomez, Ctr Estudios Econ & Sociales Salud, Direcc Invest, Secretaria Salud, Mexico City, DF, Mexico

[2] Inst Mexicano Seguro Social, Unidad Invest Econ Salud, Mexico City, DF, Mexico

[3] CEA Hlth Tech, Mexico City, DF, Mexico

来源：

SALUD PUBLICA DE MEXICO | 2012年 / 54卷 / 01期

关键词：

cost effectiveness; respiratory syncytial virus; antibodies; monoclonal; QALY; Mexico; RESPIRATORY-SYNCYTIAL-VIRUS; HIGH-RISK INFANTS; PREMATURE-INFANTS; MONOCLONAL-ANTIBODY; 1ST YEAR; INFECTION; CHILDREN; HOSPITALIZATION; BRONCHIOLITIS; RSV;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective. The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009. Results. ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for <29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760. Conclusions. Palivizumab prophylaxis for preterm newborn patients <= 32 weeks of age resulted in a cost-effective alternative.

引用

页码：47 / 59

页数：13

共 47 条

[1]

[Anonymous], 2000, National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion

[2]

Banco de Mexico, MERC CAMB

[3]

Banco de Mexico, INFL

[4] Impact of wheezing after respiratory syncytial virus infection on health-related quality of life [J].

Bont, L ;

Steijn, M ;

van Aalderen, WMC ;

Kimpen, JLL .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (05) :414-417

[5] Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease [J].

Briggs, AH ;

Goeree, R ;

Blackhouse, G ;

O'Brien, BJ .

MEDICAL DECISION MAKING, 2002, 22 (04) :290-308

[6] Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons [J].

Carbonell-Estrany, X ;

Quero, J .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (09) :874-879

[7]

Cardenas Silvia, 2005, Expert Rev Anti Infect Ther, V3, P719, DOI 10.1586/14787210.3.5.719

[8] Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis [J].

Checchia, Paul A. ;

Nalysnyk, Luba ;

Fernandes, Ancilla W. ;

Mahadevia, Parthiv J. ;

Xu, Yingxin ;

Fahrbach, Kyle ;

Welliver, Robert C., Sr. .

PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (05) :580-588

[9] Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants [J].

Chirico, Gaetano ;

Ravasio, Roberto ;

Sbarigia, Urbano .

ITALIAN JOURNAL OF PEDIATRICS, 2009, 35

[10]

Consejo Nacional de Poblacion (CONAPO), IND DEM BAS 1990 203

← 1 2 3 4 5 →